Πλοήγηση ανά Συγγραφέα "Diamantopoulos P.T., Symeonidis A., Pappa V., Kotsianidis I., Galanopoulos A., Pontikoglou C., Anagnostopoulos A., Vassilopoulos G., Zikos P., Hatzimichael E., Papaioannou M., Megalakaki A., Repousis P., Kotsopoulou M., Dimou M., Solomou E., Dryllis G., Tsokanas D., Papoutselis M.-K., Papageorgiou S., Kyrtshonis M.-C., Kourakli A., Papadaki H., Panayiotidis P., Viniou N.-A."

Αποτελέσματα 1-1 από 1

The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes

Diamantopoulos P.T., Symeonidis A., Pappa V., Kotsianidis I., Galanopoulos A., Pontikoglou C., Anagnostopoulos A., Vassilopoulos G., Zikos P., Hatzimichael E., Papaioannou M., Megalakaki A., Repousis P., Kotsopoulou M., Dimou M., Solomou E., Dryllis G., Tsokanas D., Papoutselis M.-K., Papageorgiou S., Kyrtshonis M.-C., Kourakli A., Papadaki H., Panayiotidis P., Viniou N.-A. (2021)

The regimen of 5-azacytidine for patients with myelodysplastic syndrome (MDS) has remained unchanged since its first approval. Although several modifications have since been made and delays and dose reductions are common ...